Research programme: cystic fibrosis therapeutics - FoldRx

Drug Profile

Research programme: cystic fibrosis therapeutics - FoldRx

Latest Information Update: 20 Nov 2012

Price : $50

At a glance

  • Originator FoldRx Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 19 Nov 2012 Cystic Fibrosis Foundation Therapeutics and Pfizer expand their research collaboration
  • 06 Oct 2010 FoldRx has been acquired by Pfizer
  • 09 Jul 2008 The cystic fibrosis therapeutics programme of FoldRx Pharmaceuticals is still undergoing lead discovery in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top